HKPD (Cellyan Biotechnology Co) 3-Year EBITDA Growth Rate: 0.00% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKPD Cellyan Biotechnology Co Ltd HKPD
17 GF Score
Price $0.14
! 3 Warning Signs
View Full Analysis

What is Cellyan Biotechnology Co 3-Year EBITDA Growth Rate?

Cellyan Biotechnology Co HKPD -9.09% 17 3-Year EBITDA Growth Rate is 0.00% as of Mar. 2026. GuruFocus rates HKPD with a GF Score™ of 17/100. The stock has 3 warning signs investors should review. Among 106 Medical Distribution companies, Cellyan Biotechnology Co ranks worse than 943395.28% on this metric.

Cellyan Biotechnology Co's EBITDA per Share for the six months ended in Mar. 2026 was $-0.05.

During the past 12 months, Cellyan Biotechnology Co's average EBITDA Per Share Growth Rate was -116.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Cellyan Biotechnology Co  (NAS:HKPD) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Cellyan Biotechnology Co 3-Year EBITDA Growth Rate Related Terms

HKPD vs COSM, YI, MEDS: 3-Year EBITDA Growth Rate Comparison

For the Medical Distribution subindustry, Cellyan Biotechnology Co's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cellyan Biotechnology Co 3-Year EBITDA Growth Rate vs Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Cellyan Biotechnology Co's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Cellyan Biotechnology Co's 3-Year EBITDA Growth Rate falls into.


HKPD
17GF Score
Cellyan Biotechnology Co Ltd HKPD
3-Year EBITDA Growth Rate is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cellyan Biotechnology Co 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

What does a 3-Year EBITDA Growth Rate of 0.00% mean?
Cellyan Biotechnology Co (HKPD) has a 3-Year EBITDA Growth Rate of 0.00% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Cellyan Biotechnology Co and its competitors. According to the industry distribution chart, Cellyan Biotechnology Co ranks #999999 out of 106 companies in the Medical Distribution industry.
Is Cellyan Biotechnology Co's 3-Year EBITDA Growth Rate too high?
Cellyan Biotechnology Co's current 3-Year EBITDA Growth Rate is 0.00%. Based on the distribution chart, Cellyan Biotechnology Co ranks #999999 out of 106 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Cellyan Biotechnology Co has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Cellyan Biotechnology Co's 3-Year EBITDA Growth Rate compare to COSM and YI?
According to the Medical Distribution industry distribution chart, Cellyan Biotechnology Co ranks #999999 out of 106 companies for 3-Year EBITDA Growth Rate. This places Cellyan Biotechnology Co in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 6.15. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Distribution company?
The median 3-Year EBITDA Growth Rate among Medical Distribution companies is 6.15, based on 106 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Cellyan Biotechnology Co and its competitors. For the Medical Distribution industry, the median 3-Year EBITDA Growth Rate is 6.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cellyan Biotechnology Co's current 3-Year EBITDA Growth Rate is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cellyan Biotechnology Co stock overvalued right now?
Cellyan Biotechnology Co (HKPD) has a current 3-Year EBITDA Growth Rate of 0.00%. The current 3-Year EBITDA Growth Rate is 0.00%. Cellyan Biotechnology Co's overall GF Score™ is 17/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Cellyan Biotechnology Co (HKPD), the current 3-Year EBITDA Growth Rate is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cellyan Biotechnology Co Business Description

Address 13 Ko Fai Road, Room B1, 5th Floor, Well Town Industrial Building, Yau Tong, Kowloon, Hong Kong, HKG
Cellyan Biotechnology Co Ltd formerly, Hong Kong Pharma Digital Technology Holdings Ltd operates in two main categories: OTC pharmaceutical cross-border e-commerce supply chain services, conducted through its Hong Kong subsidiary, Joint Cross Border, which it refers to as the Supply Chain Services division, and OTC pharmaceutical cross-border procurement and distribution, conducted through its Hong Kong subsidiary, V-Alliance, which it referred to as the Procurement and Distribution division. Based in Hong Kong, Joint Cross Border has established itself as a provider of third-party supply chain services in Mainland China's OTC pharmaceutical cross-border e-commerce market.
17GF Score

Get the complete analysis for HKPD

3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.14
Price